WE ARE INVESTING IN THE FUTURE OF MEDICINE.
In our view, biotechnology will be one of the most impactful sectors over the coming decades. We are convinced that preventing illness and maintaining health will be the future of healthcare, enabling people to live longer and live larger portions of their life in good health. At Korify, we focus specifically on investing innovative and visionary companies, which we think have the potential to help shape the future we envision.
THREE core
focus AREAS
We focus on backing cutting edge technologies in longevity, mental health, and regenerative medicine.
Increasing human health- and lifespan to improve quality of life
Finding novel approaches to treat people suffering from mental illness in a post-pandemic world
Regaining quality of life by reversing the devastating effects of chronic diseases.
Our
Investment approach.
Korify Capital is focused on three investment strategies: Distributed development companies, Enabling technologies and domain-specific platforms.
- Distributed development companies
- Enabling technologies
- Domain-specific platforms
Distributed development companies
A major challenge of biotech investment is that a failed clinical trial can destroy the value of a company.
DisCos (distributed development companies) solve this problem by providing infrastructure for multiple uncorrelated development programs, significantly increasing the probability that one or more programs will succeed.
As well as being a faster-maturing and capital efficient investment vehicle, DisCos has the following advantages:
- Hub functions minimize repeated infrastructure costs
- Higher quality team / easier recruiting with diversified portfolio
- Learning synergies for related assets
- Lower sunk costs and quicker decisions for unsuccessful programs
- Programs advance only on pre-defined data, not hype
Enabling technologies
For us, enabling technologies include everything from technologies improving processes or particular aspects of drug development, all the way to brain-computer interfaces.
With fast advances in science and technology, industries are being radically transformed. Through innovations in manufacturing, materials, micro-and nano electronics, AI, and connectivity among others, we see major opportunities for technology to disrupt and make healthcare more effective and efficient.
- Broad applicability
- Scalability
- Complementary risk profile to drug development
- Multiple revenue generation strategies
Domain-specific platforms
Platforms have unique and powerful capabilities to find novel targets and compounds around a certain thematic focus. Typically, they focus either on new therapeutics modalities or transforming drug discovery processes.
These platforms are usually comprised of differentiated proprietary technologies for the discovery, characterization, validation, and identification to unlock new biology and potential therapeutics. They also have strong protection around their core technology.
As a consequence, these platforms typically have multiple uncorrelated shots on one common goal.
- Scalable and target agnostic
- Interesting BD opportunities through out-licensing
- Non-binary risk profile
- Strong domain expertise attractive for M&A activity
A major challenge of biotech investment is that a failed clinical trial can destroy the value of a company.
DisCos (distributed development companies) solve this problem by providing infrastructure for multiple uncorrelated development programs, significantly increasing the probability that one or more programs will succeed.
As well as being a faster-maturing and capital efficient investment vehicle, DisCos has the following advantages:
- Hub functions minimize repeated infrastructure costs
- Higher quality team / easier recruiting with diversified portfolio
- Learning synergies for related assets
- Lower sunk costs and quicker decisions for unsuccessful programs
- Programs advance only on pre-defined data, not hype
For us, enabling technologies include everything from technologies improving processes or particular aspects of drug development, all the way to brain-computer interfaces.
With fast advances in science and technology, industries are being radically transformed. Through innovations in manufacturing, materials, micro-and nano electronics, AI, and connectivity among others, we see major opportunities for technology to disrupt and make healthcare more effective and efficient.
- Broad applicability
- Scalability
- Complementary risk profile to drug development
- Multiple revenue generation strategies
Platforms have unique and powerful capabilities to find novel targets and compounds around a certain thematic focus. Typically, they focus either on new therapeutics modalities or transforming drug discovery processes.
These platforms are usually comprised of differentiated proprietary technologies for the discovery, characterization, validation, and identification to unlock new biology and potential therapeutics. They also have strong protection around their core technology.
As a consequence, these platforms typically have multiple uncorrelated shots on one common goal.
- Scalable and target agnostic
- Interesting BD opportunities through out-licensing
- Non-binary risk profile
- Strong domain expertise attractive for M&A activity
A team committed to helping people realize their full potential.
Davide Ottolini
Davide is an experienced investor with deep knowledge of the financial industry and the healthcare and biotech space. After working as a consultant for big pharma for several years with EY, he co-founded and co-leads Korify Capital as well as other projects within the biotech space. He holds a bachelor of arts in Business and Economics from the University of Basel.
Robin Lauber
Robin is a serial angel investor and entrepreneur, having co-founded his family office Infinitas Capital, the real estate company GreySky Properties Holding AG and Korify Capital, among other entrepreneurial endeavours. He looks back on over 10 years of VC and Real Estate investing as well as incubating, building and scaling numerous ventures. He graduated from Basel University with a BSc in Business Administration and Cass Business School with a MSc in Entrepreneurship.
Get involved
for further information.
Please contact us anytime should you have questions. We are looking forward to getting in touch with you.